Is High-Intensity Exercise Bad For Rheumatic Diseases?

The systematic review by Jean‑Pascal gathered every trial describing its protocol as high‑intensity—typically over 70 % of maximal heart rate and including aerobic, strength and interval formats. Among 1,300 patients with rheumatoid arthritis, axial spondyloarthritis and related conditions, no evidence emerged that such regimens damage joints. Primary outcomes—pain, functional ability and perceived disability—matched or exceeded those of low‑or moderate‑intensity programs, and several secondary measures, like sit‑to‑stand performance, favored high‑intensity groups. Adverse events were minimal, with less than one percent withdrawing for safety reasons.

These findings challenge long‑standing rheumatology guidelines that advise caution and low‑dose activity. Modern disease‑modifying therapies now control inflammation early, allowing patients to tolerate more vigorous exercise. High‑intensity training also combats common comorbidities—osteoporosis, metabolic syndrome and cardiovascular risk—by boosting bone density, insulin sensitivity and systemic inflammation markers. Consequently, exercise shifts from a protective, minimal prescription to a potent, multimodal intervention that can be customized to individual disease activity and functional goals. Patients reporting higher disease activity also showed reductions in inflammatory biomarkers after high‑intensity protocols.

Future research must address the gaps highlighted by the review, especially the scarcity of randomized trials in lupus and other connective‑tissue diseases, and identify which patient subgroups gain the most long‑term advantage. Practical barriers—limited equipment in group physiotherapy, entrenched clinician hesitancy, and NHS resource constraints—require targeted education and revised guideline language that explicitly endorses high‑intensity options when appropriate. Pilot programs integrating gym‑based modules with tele‑monitoring have shown promising adherence rates. By embedding personalized intensity prescriptions into routine rheumatology care, clinicians can safely expand the therapeutic reach of exercise for patients across the disease spectrum.